Literature DB >> 10475273

Parabolic growth patterns in 96-well plate cell growth experiments.

H M Faessel1, L M Levasseur, H K Slocum, W R Greco.   

Abstract

In preparing for the routine use of the ubiquitous in vitro cell growth inhibition assay for the study of anticancer agents, we characterized the statistical properties of the assay and found some surprising results. Parabolic well-to-well cell growth patterns were discovered, which could profoundly affect the results of routine growth inhibition studies of anticancer and other agents. Four human ovarian cell lines, A2780/WT, A2780/DX5, A2780/DX5B, and A121, and one human ileocecal adenocarcinoma cell line, HCT-8, were seeded into plastic 96-well plates with a 12-channel pipette, without drugs, and grown from 1-5 d. The wells were washed with a plate washer, cells stained with sulforhodamine B (SRB), and dye absorbance measured with a plate reader. Variance models were fit to the data from replicates to determine the nature of the heteroscedastic error structure. Exponential growth models were fit to data to estimate doubling times for each cell line. Polynomial models were fit to data from 10-plate stacks of 96-well plates to explore nonuniformity of cell growth in wells in different regions of the stacks. Each separate step in the assay was examined for precision, patterns, and underlying causes of variation. Differential evaporation of water from wells is likely a major, but not exclusive, contributor to the systematic well-to-well cell growth patterns. Because the fundamental underlying causes of the parabolic growth patterns were not conclusively found, a randomization step for the growth assay was developed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475273     DOI: 10.1007/s11626-999-0071-z

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  10 in total

1.  Characterization of human ovarian and endometrial carcinoma cell lines established on extracellular matrix.

Authors:  K Crickard; M J Niedbala; U Crickard; M Yoonessi; A A Sandberg; K Okuyama; R J Bernacki; S K Satchidanand
Journal:  Gynecol Oncol       Date:  1989-02       Impact factor: 5.482

2.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

3.  Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays.

Authors:  G M Ferron; N A Pyszczynski; W J Jusko
Journal:  Transplantation       Date:  1998-05-15       Impact factor: 4.939

4.  Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933.

Authors:  M A Alaoui Jamali; M B Yin; A Mazzoni; I Bankusli; Y M Rustum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells.

Authors:  L M Levasseur; W R Greco; Y M Rustum; H K Slocum
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

6.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

7.  Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

Authors:  L V Rubinstein; R H Shoemaker; K D Paull; R M Simon; S Tosini; P Skehan; D A Scudiero; A Monks; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Reversal of adriamycin resistance by verapamil in human ovarian cancer.

Authors:  A M Rogan; T C Hamilton; R C Young; R W Klecker; R F Ozols
Journal:  Science       Date:  1984-06-01       Impact factor: 47.728

Review 9.  The National Cancer Institute: cancer drug discovery and development program.

Authors:  M R Grever; S A Schepartz; B A Chabner
Journal:  Semin Oncol       Date:  1992-12       Impact factor: 4.929

10.  PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.

Authors:  U Vanhoefer; S Cao; H Minderman; K Tóth; R J Scheper; M L Slovak; Y M Rustum
Journal:  Clin Cancer Res       Date:  1996-02       Impact factor: 12.531

  10 in total
  4 in total

1.  The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells.

Authors:  Rami G Azrak; Cheryl L Frank; Xiang Ling; Harry K Slocum; Fengzhi Li; Barbara A Foster; Youcef M Rustum
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

2.  Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.

Authors:  Yseult F Brun; Carly G Dennis; William R Greco; Ralph J Bernacki; Paula J Pera; Jennifer J Bushey; Richard C Youn; Donald B White; Brahm H Segal
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

3.  Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Ioannis Tsiouris; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

Review 4.  Phenotypic Screening in C. elegans as a Tool for the Discovery of New Geroprotective Drugs.

Authors:  Sven Bulterijs; Bart P Braeckman
Journal:  Pharmaceuticals (Basel)       Date:  2020-07-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.